View in EDS

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.

Saved in:
Bibliographic Details
Title: Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
Authors: Bonnefoi, Hervé1 (AUTHOR) h.bonnefoi@bordeaux.unicancer.fr, Lerebours, Florence2 (AUTHOR), Pulido, Marina3 (AUTHOR), Arnedos, Monica4 (AUTHOR), Tredan, Olivier5 (AUTHOR), Dalenc, Florence6 (AUTHOR), Guiu, Séverine7 (AUTHOR), Teixeira, Luis8 (AUTHOR), Mollon, Delphine9 (AUTHOR), Levy, Christelle10 (AUTHOR), Verret, Benjamin11 (AUTHOR), Dawood, Heba12 (AUTHOR), Deiana, Laura13 (AUTHOR), Mouret Reynier, Marie-Ange14 (AUTHOR), Augereau, Paule15 (AUTHOR), Canon, Jean-Luc16 (AUTHOR), Huchet, Noémie17 (AUTHOR), Guyonneau, Clara18 (AUTHOR), Lemonnier, Jérôme18 (AUTHOR), MacGrogan, Gaetan19 (AUTHOR)
Source: Lancet Oncology. Mar2025, Vol. 26 Issue 3, p355-366. 12p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(24)00737-X